Sutro Biopharma registers Phase 1 first-in-human trial of ADC STRO-006 in solid tumors
New registry listing outlines a three-part Phase 1 study of STRO-006 alone and with pembrolizumab in refractory solid tumors, not yet recruiting.
Sutro Biopharma had one new trial registration for the week of September 8, 2026.
- Sutro Biopharma listed a Phase 1 open-label, first-in-human study (NCT07807345) of its antibody drug conjugate STRO-006 in adults with refractory solid tumors that are recurrent or metastatic. The trial is not yet recruiting, with an estimated start of 2026-09-141, and is designed in three parts covering dose escalation of STRO-006 monotherapy in tumor types that commonly express ITGB6, a dose expansion phase to determine the recommended Phase 2 dose, and a combination dose escalation of STRO-006 with pembrolizumab1. The study plans to enroll 285 participants across conditions including head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal cancer, gastric cancer, colorectal cancer, endometrial cancer, urothelial carcinoma, and breast cancer1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.